The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Today we hit the road running with our campaign, ‘Time for $5’, calling on the US company Cepheid, and its parent corporation Danaher, to drop the price of a lifesaving test, GeneXpert, to save millions of people’s lives around the world.
